+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Global Cardiac Arrhythmias Therapeutics Market 2019-2023 - Product Image

Global Cardiac Arrhythmias Therapeutics Market 2019-2023

  • ID: 4808289
  • Report
  • July 2019
  • Region: Global
  • 130 pages
  • TechNavio
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 4

FEATURED COMPANIES

  • Bayer AG
  • Eli Lilly and Co.
  • GlaxoSmithKline Plc
  • Pfizer Inc.
  • Sanofi.
  • MORE
Global Cardiac Arrhythmias Therapeutics Market: About this market

Cardiac arrhythmias therapeutics are pharmaceutical agents that are used to normalize the issue of cardiac arrhythmia. The cardiac arrhythmias therapeutics market analysis considers sales from both oral and intravenous applications. Our analysis also considers the sales of cardiac arrhythmias therapeutics in North America, Europe, Asia and the rest of the world (ROW). In 2018, the oral segment had a significant market share, and this trend is expected to continue over the forecast period. Factors such as Low cost, easy to consume, no pain, extended-release effect of oral arrhythmias therapeutics will play a significant role in the oral segment to maintain its market position. Also, our global cardiac arrhythmias therapeutics market report also looks at factors such as the growing prevalence of thrombosis, availability of precise diagnostic methods, rising awareness about cardiovascular diseases. However, black box warning associated with cardiac arrhythmias therapeutics, availability of substitute products, stringent regulatory environment may hamper the growth of the cardiac arrhythmias therapeutics industry over the forecast period.

Global Cardiac Arrhythmias Therapeutics Market: Overview

Availability of precise diagnostic methods

The availability of precise diagnostic methods, like electrocardiogram (ECG) Hotter monitors, event monitors, stress IQ tests, echocardiogram, cardiac catheterization, electrophysiology study (EPS), and head-up tiff table tests have led to increase in the diagnosis rate of cardiac arrhythmias, thus contributing to increased prescription of therapeutics for cardiac arrhythmias. Such factors will lead to the expansion of the global cardiac arrhythmias therapeutics market at a CAGR of over 4% during the forecast period.

The advent of gene therapy to control ventricular rate in AF

The current treatment therapy for AF involves the use of antiarrhythmic drugs to sustain the sinus rhythm or drugs that can curb the conduction in the atrioventricular (AV) node in order to control the ventricular rate. The medication therapy used for the treatment of arrhythmia exerts its pharmacological effect by targeting the conduction properties of the AV node- by suppressing the calcium current or by altering the cholinergic and adrenergic tone. Therefore, the global cardiac arrhythmias therapeutics market presents an urgent need for the development of biological drugs, which can target the gene and thus, improve cardiac functioning. Ongoing research in this area is expected to have a positive impact on market growth during the forecast period.

Competitive Landscape

With the presence of several major players, the global cardiac arrhythmias therapeutics market is fragmented. The robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading cardiac arrhythmias therapeutics manufacturers, that include Bayer AG, Eli Lilly and Co., GlaxoSmithKline Plc, Pfizer Inc., and Sanofi.

Also, the cardiac arrhythmias therapeutics market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage on all forthcoming growth opportunities.
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Bayer AG
  • Eli Lilly and Co.
  • GlaxoSmithKline Plc
  • Pfizer Inc.
  • Sanofi.
  • MORE
PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT
  • Preface
  • Currency conversion rates for US$
PART 03: MARKET LANDSCAPE
  • Market ecosystem
  • Market characteristics
  • Market segmentation analysis
PART 04: MARKET SIZING
  • Market definition
  • Market sizing 2018
  • Market size and forecast 2018-2023
PART 05: FIVE FORCES ANALYSIS
  • Bargaining power of buyers
  • Bargaining power of suppliers
  • Threat of new entrants
  • Threat of substitutes
  • Threat of rivalry
  • Market condition
PART 06: MARKET SEGMENTATION BY APPLICATION
  • Market segmentation by application
  • Comparison by application
  • Oral - Market size and forecast 2018-2023
  • Intravenous - Market size and forecast 2018-2023
  • Market opportunity by application
PART 07: CUSTOMER LANDSCAPE

PART 08: GEOGRAPHIC LANDSCAPE
  • Geographic segmentation
  • Geographic comparison
  • North America - Market size and forecast 2018-2023
  • Europe - Market size and forecast 2018-2023
  • Asia - Market size and forecast 2018-2023
  • ROW - Market size and forecast 2018-2023
  • Key leading countries
  • Market opportunity
PART 09: DECISION FRAMEWORK

PART 10: DRIVERS AND CHALLENGES
  • Market drivers
  • Market challenges
PART 11: MARKET TRENDS
  • The advent of gene therapy to control ventricular rate in AF
  • Technological advances enabling the early detection of cardiac arrhythmias
  • Growing R&D efforts by vendors
PART 12: VENDOR LANDSCAPE
  • Overview
  • Landscape disruption
  • Competitive scenario
PART 13: VENDOR ANALYSIS
  • Vendors covered
  • Vendor classification
  • Market positioning of vendors
  • Bayer AG
  • Eli Lilly and Co.
  • GlaxoSmithKline Plc
  • Pfizer Inc.
  • Sanofi
PART 14: APPENDIX
  • Research methodology
  • List of abbreviations
  • Definition of market positioning of vendors
List of Exhibits:
Exhibit 01: Product overview
Exhibit 02: Global pharmaceuticals market
Exhibit 03: Segments of global pharmaceuticals market
Exhibit 04: Market characteristics
Exhibit 05: Market segments
Exhibit 06: Market definition - Inclusions and exclusions checklist
Exhibit 07: Market size 2018
Exhibit 08: Global market: Size and forecast 2018-2023 ($ millions)
Exhibit 09: Global market: Year-over-year growth 2019-2023 (%)
Exhibit 10: Five forces analysis 2018
Exhibit 11: Five forces analysis 2023
Exhibit 12: Bargaining power of buyers
Exhibit 13: Bargaining power of suppliers
Exhibit 14: Threat of new entrants
Exhibit 15: Threat of substitutes
Exhibit 16: Threat of rivalry
Exhibit 17: Market condition - Five forces 2018
Exhibit 18: Application - Market share 2018-2023 (%)
Exhibit 19: Comparison by application
Exhibit 20: Oral - Market size and forecast 2018-2023 ($ millions)
Exhibit 21: Oral - Year-over-year growth 2019-2023 (%)
Exhibit 22: Intravenous - Market size and forecast 2018-2023 ($ millions)
Exhibit 23: Intravenous - Year-over-year growth 2019-2023 (%)
Exhibit 24: Market opportunity by application
Exhibit 25: Customer landscape
Exhibit 26: Market share by geography 2018-2023 (%)
Exhibit 27: Geographic comparison
Exhibit 28: North America - Market size and forecast 2018-2023 ($ millions)
Exhibit 29: North America - Year-over-year growth 2019-2023 (%)
Exhibit 30: Top 3 countries in North America
Exhibit 31: Europe - Market size and forecast 2018-2023 ($ millions)
Exhibit 32: Europe - Year-over-year growth 2019-2023 (%)
Exhibit 33: Top 3 countries in Europe
Exhibit 34: Asia - Market size and forecast 2018-2023 ($ millions)
Exhibit 35: Asia - Year-over-year growth 2019-2023 (%)
Exhibit 36: Top 3 countries in Asia
Exhibit 37: ROW - Market size and forecast 2018-2023 ($ millions)
Exhibit 38: ROW - Year-over-year growth 2019-2023 (%)
Exhibit 39: Top 3 countries in ROW
Exhibit 40: Key leading countries
Exhibit 41: Market opportunity
Exhibit 42: Diagnostic methods
Exhibit 43: Side-effects of cardiac arrhythmias therapeutics
Exhibit 44: Substitute products to cardiac arrhythmias therapeutics
Exhibit 45: Impact of drivers and challenges
Exhibit 46: Vendor landscape
Exhibit 47: Landscape disruption
Exhibit 48: Vendors covered
Exhibit 49: Vendor classification
Exhibit 50: Market positioning of vendors
Exhibit 51: Bayer AG - Vendor overview
Exhibit 52: Bayer AG - Business segments
Exhibit 53: Bayer AG - Organizational developments
Exhibit 54: Bayer AG - Geographic focus
Exhibit 55: Bayer AG - Segment focus
Exhibit 56: Bayer AG - Key offerings
Exhibit 57: Bayer AG - Key customers
Exhibit 58: Eli Lilly and Co. - Vendor overview
Exhibit 59: Eli Lilly and Co. - Business segments
Exhibit 60: Eli Lilly and Co. - Organizational developments
Exhibit 61: Eli Lilly and Co. - Geographic focus
Exhibit 62: Eli Lilly and Co. - Segment focus
Exhibit 63: Eli Lilly and Co. - Key offerings
Exhibit 64: Eli Lilly and Co. - Key customers
Exhibit 65: GlaxoSmithKline Plc - Vendor overview
Exhibit 66: GlaxoSmithKline Plc - Business segments
Exhibit 67: GlaxoSmithKline Plc - Organizational developments
Exhibit 68: GlaxoSmithKline Plc - Geographic focus
Exhibit 69: GlaxoSmithKline Plc - Segment focus
Exhibit 70: GlaxoSmithKline Plc - Key offerings
Exhibit 71: GlaxoSmithKline Plc - Key customers
Exhibit 72: Pfizer Inc. - Vendor overview
Exhibit 73: Pfizer Inc. - Business segments
Exhibit 74: Pfizer Inc. - Organizational developments
Exhibit 75: Pfizer Inc. - Geographic focus
Exhibit 76: Pfizer Inc. - Segment focus
Exhibit 77: Pfizer Inc. - Key offerings
Exhibit 78: Pfizer Inc. - Key customers
Exhibit 79: Sanofi - Vendor overview
Exhibit 80: Sanofi - Business segments
Exhibit 81: Sanofi - Organizational developments
Exhibit 82: Sanofi - Geographic focus
Exhibit 83: Sanofi - Segment focus
Exhibit 84: Sanofi - Key offerings
Exhibit 85: Sanofi - Key customers
Exhibit 86: Validation techniques employed for market sizing
Exhibit 87: Definition of market positioning of vendors
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4

FEATURED COMPANIES

  • Bayer AG
  • Eli Lilly and Co.
  • GlaxoSmithKline Plc
  • Pfizer Inc.
  • Sanofi.
  • MORE
The following companies are recognised as the key players in the global cardiac arrhythmias therapeutics market: Bayer AG, Eli Lilly and Co., GlaxoSmithKline Plc, Pfizer Inc., and Sanofi.

Commenting on the report, an analyst from the research team said: “The latest trend gaining momentum in the market is the advent of gene therapy to control ventricular rate in AF.”

According to the report, one of the major drivers for this market is the availability of precise diagnostic methods.

Further, the report states that one of the major factors hindering the growth of this market is the stringent regulatory environment.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Note: Product cover images may vary from those shown
5 of 4
  • Bayer AG
  • Eli Lilly and Co.
  • GlaxoSmithKline Plc
  • Pfizer Inc.
  • Sanofi.
Note: Product cover images may vary from those shown
Adroll
adroll